PharmX Technologies Limited EBIT

PharmX Technologies Limited (PHX.AX) currently reports a EBIT of $-2.1M as of June 2026. That compares with $-360K in the prior-year period — down 487.1% year over year. That is below the Technology sector average of $80T. Use the charts on this page to explore PharmX Technologies Limited's EBIT history and peer comparisons.

PharmX Technologies Limited's EBIT decreased from $-360K to $-2.1M — a 487.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PharmX Technologies Limited's EBIT of $-2.1M is lower than the Technology sector average of $80T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PharmX Technologies Limited reported $-2.1M in EBIT as of June 2026. That compares with $-360K in the prior-year period — down 487.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-2.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is $80T. From there, open related valuation or income-statement pages for PharmX Technologies Limited, and consider following PHX.AX for alerts when major investors trade the stock.